MA
PPH icon

MCF Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

MCF Advisors’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Hold
100
– – ﹤0.01% 1025
2026
Q1 		$10.4K Hold
100
– – ﹤0.01% 958
2025
Q4 		$10.3K Buy
+100
New +$9.73K ﹤0.01% 827

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

MCF Advisors's PPH Position: Q2 2026 in Review

MCF Advisors held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2026 at 100 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1025.

MCF Advisors first reported a position in PPH in Q4 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • MCF Advisors held 100 shares of VanEck Pharmaceutical ETF worth $10.9K as of Q2 2026.
  • MCF Advisors left its VanEck Pharmaceutical ETF share count unchanged in Q2 2026.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1025 holding.
  • MCF Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.